Hearing on “Examining Concerns Regarding FDA’s Proposed Changes to Generic Drug Labeling,” Subcommittee on Health (April 1, 2014)

Subcommittee on Health (113th Congress)
Apr 1, 2014
2322 Rayburn House Office Building

The Subcommittee on Health held a hearing on Tuesday, April 1, 2014, at 3:00 p.m. in 2322 Rayburn House Office Building.  The hearing was entitled “Examining Concerns Regarding FDA’s Proposed Changes to Generic Drug Labeling.” 

Documents

Memorandum from Ranking Member Henry A. Waxman to Democratic Members of the Subcommittee on Health

Opening Statement of Ranking Member Henry A. Waxman, as prepared for delivery.

Preliminary Transcript

 

Witnesses

Panel I

Janet Woodcock, M.D.
Director, Center for Drug Evaluation and Research
U.S. Food and Drug Administration (FDA)
Testimony

Panel II

Michael D. Shumsky
Partner
Kirkland & Ellis LLP
Testimony

Ralph G. Neas
President and CEO
Generic Pharmaceutical Association
Testimony

Allison M. Zieve
General Counsel
Public Citizen
Testimony

 

Webcast

113th Congress